Where does Shanghai Hengrui Pharmaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Shanghai Hengrui Pharmaceutical Co., Ltd. ranks #4,262 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Shanghai Hengrui Pharmaceutical Co., Ltd. hold?

Shanghai Hengrui Pharmaceutical Co., Ltd. holds 84 US utility patents granted between 2015 and 2025, spanning 13 technology areas.

What is Shanghai Hengrui Pharmaceutical Co., Ltd.'s Innovation Score?

Shanghai Hengrui Pharmaceutical Co., Ltd. has an Innovation Score of 43.4 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Shanghai Hengrui Pharmaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Shanghai Hengrui Pharmaceutical Co., Ltd.'s recent grant velocity is +77% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Shanghai Hengrui Pharmaceutical Co., Ltd.'s patents?

Shanghai Hengrui Pharmaceutical Co., Ltd.'s patents average 17.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Shanghai Hengrui Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shanghai Hengrui Pharmaceutical Co., Ltd.

Q: What technology areas does Shanghai Hengrui Pharmaceutical Co., Ltd. focus on?

Shanghai Hengrui Pharmaceutical Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 82 patents. Grants appear in 13 CPC subclasses total.

USPTO PatentsView assignee record - 84 granted patents across 13 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Shanghai ranks #4,262 of 49,997 tracked US assignees by granted-patent volume, with 84 patents across 13 technology areas.

#4,262
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.4/100): 17.9
avg claims per patent: +77%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4262 · Foreign Corporation #4,262 · 84 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 84 grants
TOP-DECILE #4,262/49,997
PHOTO-FINISH Qualcomm Mems
CPC-FOCUS A61P · 13 areas
INNOV-PAR 43.4/100
CLAIMS-RICH 17.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +77% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Qualcomm Mems Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Adesto · near

43
Shanghai Hengrui… · this assignee

43
Bruker Biospin · near

43
Gemtek Technology · near

43
Hindustan Petroleum · near

43
3D Lighting… · lowest

7

What this shows Shanghai's Innovation Score is 43.4/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Shanghai's grants concentrate

Shanghai Hengrui Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 13 CPC subclasses with 97.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (16 grants) versus a trough of 2 in 2015. By volume, Shanghai sits between Qualcomm Mems Technologies, Inc. and Seville Classics Inc..

Shanghai's three-year grant acceleration

From 2019–2021 to 2022–2024, Shanghai Hengrui Pharmaceutical Co., Ltd. moved from 34 to 23 grants (0.68x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Qualcomm Mems

84
Quanata

84
Refinitiv US Orga…

84
Riddell

84
Soclean

84
Somfy Activites

84
Spatial Digital S…

84
Seville Classics

84
Shanghai Hengrui… ◀

84

What this shows Shanghai holds 84 patents at rank #4,261, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Shanghai

By rank, the assignees closest to #4,261 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Shanghai's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Shanghai, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (43 here).

Adesto Technologies Corporation 43 Bruker Biospin GmbH 43 Hindustan Petroleum Corporation Limited 43 Gemtek Technology Co., Ltd. 43

Similar claim depth

Nearest assignees by average claims per patent (17.9 here).

Edge 3 Technologies 17.9 avg The Medical College of Wisconsin, Inc. 17.9 avg Silanna Asia Pte Ltd 17.9 avg Eastman Chemical Company 17.9 avg

Shanghai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Shanghai Hengrui Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	2.4%
2016	3	3.6%
2017	2	2.4%
2018	8	9.5%
2019	11	13.1%
2020	10	11.9%
2021	13	15.5%
2022	16	19.0%
2023	3	3.6%
2024	4	4.8%
2025partial year	12	14.3%

Which technologies does Shanghai Hengrui Pharmaceutical Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 82

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 70

C07D - Heterocyclic Compounds 46

C07K - Peptides 36

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C07C - Acyclic OR Carbocyclic Compounds 6

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 6

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 13 of 13 technology areas

Where it ranks

Overall rank by patents

#4,262

of 49,997 tracked assignees

Innovation Score

43.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Shanghai Hengrui Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

Shanghai Hengrui Pharmaceutical Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 97.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,262 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Shanghai Hengrui Pharmaceutical Co., Ltd. against Qualcomm Mems Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.